Study Stopped
Unable to enroll suitable subjects
Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator
ACAB
1 other identifier
observational
60
1 country
1
Brief Summary
Evaluate data accuracy of cardiac acoustic biomarkers (CABs) recorded by the Wearable Cardioverter Defibrillator (WCD) as compared to the AUDICOR AM acoustic cardiography recorder.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 23, 2020
CompletedFirst Submitted
Initial submission to the registry
February 28, 2020
CompletedFirst Posted
Study publicly available on registry
March 3, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2025
CompletedOctober 30, 2025
October 1, 2025
5.7 years
February 28, 2020
October 28, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
CABs comparison
Simultaneous CABs recordings from the AUDICOR and WCD devices will be compared
2 hours
Study Arms (1)
Heart Failure Patients
Simultaneous recordings of cardiac acoustic biomarkers (CABs) by the Wearable Cardioverter Defibrillator and the AUDICOR AM
Interventions
Use of the Wearable Cardioverter Defibrillator and AUDICOR AM to evaluate accuracy of cardiac acoustic biomarker recordings.
Eligibility Criteria
Primary Care, Heart Failure, and Cardiology
You may qualify if:
- years of age or older
- heart failure or a history of heart failure
- ischemic or non-ischemic cardiomyopathy
- ejection Fraction less than or equal to 40% as measured within the last 6 months
You may not qualify if:
- implanted left ventricular assist device
- pacemaker dependency
- currently hospitalized
- atrial fibrillation on their last ECG or having an irregularly irregular pulse
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
MAYO Clinic
Rochester, Minnesota, 55905, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Mike Osz
Director, Clinical Operations, ZOLL
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 28, 2020
First Posted
March 3, 2020
Study Start
January 23, 2020
Primary Completion
September 30, 2025
Study Completion
September 30, 2025
Last Updated
October 30, 2025
Record last verified: 2025-10
Data Sharing
- IPD Sharing
- Will not share